Organic Active Ingredients TRIZ Cases

A low-pH liposomal Centella and AHA emulsion reduces senescent skin cells, inflammation, and fibroblast decline in dermatoporosis.

Direct 5-HT2A receptor binding by indoline compounds aims to treat psychosis and CNS disorders without hallucinogenic effects.

A segmented 5'-UTR, ORF, and 3'-UTR design improves mRNA stability, translation efficiency, and vaccine immunogenicity.

Fluorinated aryl hydantoin compounds extend half-life, target juvenile schistosomula, and reduce antiandrogenic effects in schistosomiasis treatment.

Combining resin-bound immediate and barrier-coated release phases gives amphetamine tablets fast onset and a stable 13-hour effect, even when chewed.

Novel TRPV2 blockers selectively inhibit tumor and inflammatory TRPV2 activity while minimizing healthy-cell cytotoxicity.

Phosphate esterification makes budesonide water-soluble and stable, enabling uniform nebulizer formulations without deposition or additives.

Adding a volatile solvent lowers in-situ gel viscosity for filtration sterilization, then solvent removal cuts degradation and impurities.

Selecting mesenchymal stem cells with high HLA-A2 expression suppresses TNF-α and boosts CD163 and Arg-1 for inflammatory disease treatment.

Connexin and NLRP3 inflammasome modulators target inflammation and cellular signaling to relieve long COVID and related post-acute symptoms.

A calcium phosphate putty uses iron excipients for visible mixing, X-ray contrast, controlled agent delivery, and safer bone defect repair.

A 9β,10α neurosteroid prolongs GABA-activated chloride channel opening to improve CNS disorder treatment with better stability and fewer side effects.

Selective p38 MAPK inhibition lowers severe influenza cytokine release while preserving protective immune response and limiting respiratory complications.

Targeting autotaxin with a modified aptamer suppresses RPE proliferation and migration to help prevent proliferative vitreoretinopathy.

Region-specific GI sampling guides antimicrobial susceptibility testing and targeted delivery for personalized SIBO treatment.

Crushed cartridge emulsion is released through microneedles, using heat or ultrasound to improve dermal absorption while minimizing skin irritation.

Combining core and outer nicotine formulations enables fast and extended release with varied organoleptic properties in one dosage form.

EDTA and a sulfated polysaccharide stabilize isoproterenol in microneedle coatings, enabling higher drug loading during production and storage.

Cyclodextrin and non-sulphonic acid keep gedatolisib in a clear, particle-free aqueous solution for therapeutic intravenous dosing.

Polymer-linked SN22 uses labile ester bonds to sustain intratumoral drug levels in neuroblastoma while limiting systemic toxicity.

Targeting HIF-1α with fursultiamine suppresses choroidal neovascularization and vascular leakage while avoiding frequent anti-VEGF injections.

Targeting KDM1A with vafidemstat addresses non-aggressive borderline personality disorder symptoms while avoiding the side effects of off-label drugs.

By targeting TGR5 to trigger GLP-1 secretion, cholic acid 7-sulfate derivatives improve glucose tolerance and insulin sensitivity.

Adding hydroxycitric acid during T cell culture improves persistence, antitumor activity, and survival while reducing apoptosis.

A single formulation combining beta-blocker, sartan, and optional diuretic improves blood pressure control while reducing regimen complexity and side effects.

A single intravitreal rAAV2 dose enables sustained aflibercept expression, reducing repeat anti-VEGF injections and related eye complications.

Sequential channel mixing forms uniform lipid nanoparticles without sorting while lowering ionizable lipid content and toxicity risk.

Hot-melt extruded posaconazole granules with enteric polymers stabilize dissolution and improve bioavailability with less food effect.

Genetic detection of mutant SPOP guides AKT plus BET inhibitor therapy to resensitize resistant cancers, including prostate cancer.

Electrospinning decellularized ECM with a temporary synthetic polymer yields reproducible, biocompatible scaffolds with native-like structure.

Ascorbyl palmitate is added to methylphenidate formulations to intercept nitrosation and reduce carcinogenic nitrosamine formation.

Small-molecule 4-alkoxybenzimidazole compounds maintain GLP-1 agonist activity while enabling oral dosing instead of peptide injection.

A 4-bromobutyric acid linker enables a highly pure HA-paclitaxel conjugate while avoiding Cremophor EL reactions and dialysis.

Low molecular weight ferroportin-inhibitor salts help prevent iron transport, improving stability and reducing toxicity in iron overload treatment.

A spring-driven bi-dose nasal spray delivers two equal midazolam doses in any patient position without priming, improving hygiene and dosing accuracy.

An oral HD tablet combines Compound 1 with excipients to reduce HTT mRNA and protein while slowing motor, cognitive, and psychiatric decline.

A three-step exatecan route uses mild acid-catalyzed inversion and cyclization to raise yield, simplify isomer control, and cut scale-up cost.

GalNAc-conjugated PD-L1 siRNA improves liver-specific delivery and mRNA inhibition while reducing systemic side effects and extending dosing intervals.

Biased MC4R agonists restore impaired NFAT signaling in deficiency-linked obesity, enabling treatment selection for like-wild-type mutations.

Novel Formula I capsid inhibitor compounds target drug-resistant HIV while improving stability and pharmacokinetic profiles.

A mixed organic acid feed additive lowers viral load in contaminated animal feed and helps reduce infection risk and clinical symptoms.

Patient monitoring and machine learning reshape non-linear opioid tapering plans to address withdrawal, anxiety, and side effects.

A palladium-catalyzed route to Compound IX raises yield and purity while using commercially available starting materials to lower synthesis cost.

An oral composition of a cereblon-binding compound improves multiple myeloma response while reducing toxicity and supporting stable formulation.

Co-administering polymyxins with aminoglycosides in a dry powder inhaler reduces lung toxicity while improving aerosolization for respiratory infections.

A stable pyridinylphenyl crystal form complexes with aldehydes, penetrates the cornea, and reduces dry eye inflammation and toxicity.

Biomarker shifts after treatment help predict cancer therapy sensitivity early, avoiding months of waiting for clinical response assessment.

Formula I compounds selectively inhibit TYK2 to treat inflammatory disorders while limiting side effects from broader JAK inhibition.

An oxygen-carrying perfusion composition uses erythrocruorin and folate/BH4 micronutrients to limit ischemic damage and reperfusion injury.

NTRK/ALK/ROS1 inhibitors combined with venetoclax restore apoptosis in resistant AML linked to low TP53 expression or TP53 mutation.

Natural compounds target menopausal sleep disturbances without common side effects.

This case uses RAGE antagonists or AGE scavengers to inhibit harmful signaling and reduce diabetic stroke brain injury.

This case uses endothelial-targeted let-7 miRNA nanoparticles to inhibit disease-driving pathways and reverse atherosclerotic lesions.

Hydrolysable lipidoids help LNPs maintain delivery potency while reducing liver toxicity and immunogenicity for in vivo therapy.

This case uses PIPA as a pseudo-transcription factor to inhibit protozoan morphological change and support malaria treatment.

This case uses ensifentrine for low-eosinophil COPD to improve trough lung function and reduce exacerbation frequency and severity.

Mannitol and disaccharides stabilize collagenase during faster lyophilization.

This case modifies briarane structures to improve iNOS and COX-2 inhibition, potency, and solubility for inflammatory conditions.

Brain-penetrant Formula (I) compounds selectively inhibit HDAC6 for neurological disease and cancer while limiting off-target HDAC effects.

This case combines filler rheology with landmark-based planning to target temporal deficits while avoiding vascular and nerve risks.

This case uses partial deuterated PUFA substitution to inhibit dermal lipid peroxidation, reducing wrinkles and unpleasant odors.

This case uses selected deuterium positions in Sabizabulin to improve metabolic stability, half-life, and pharmacokinetic predictability.

This case uses an anti-CD179a antibody-drug conjugate to disrupt pre-BCR signaling, sensitize B-ALL cells, and limit off-target toxicity.

This case uses lysosomal iron to activate salinomycin and narasin derivatives, inducing ferroptosis in resistant cancer and stem cells.

Novel substituted butenyl compounds combine receptor recognition with covalent inhibition to address ERα therapy resistance.

This case uses substituted quinoline compounds to enhance SERCA activity, restore ER homeostasis, and address disease-related ER stress.

Combining irinotecan with KRAS G12D inhibitors addresses intrinsic resistance.

This case pairs SBE-β-CD with xanthan gum to prevent brimonidine precipitation and preserve transparent, stable ophthalmic solutions.

A spray-dried amorphous dispersion in HPMCAS or PVP/VA supports stable oral delivery for acromegaly and neuroendocrine tumors.

This composition uses SGLT-2 inhibition to reduce endothelial senescence and address cardiovascular aging diseases.

This case uses esterified cannabidiol derivatives as oral prodrugs to improve absorption, prolong action, and reduce adverse effects.

This case uses USP1 inhibition to destabilize replication forks and reduce viability in BRCA1/2-mutated cancers.

This case uses pyridazine-containing compounds to increase EAAT2 expression, enhance glutamate reuptake, and reduce neuronal damage.

This case uses localized OGFR antagonists to recruit MSCs, enhance mineralization, and support bone healing without BMP-related tumor risk.

This case uses dimpled, biodegradable microspheres in microneedles to resist skin elasticity and prolong drug release.

This oral composition combines chlorogenic acid, caffeine, and 4-vinylguaiacol to preserve physiological effects while reducing harshness.

This case combines CDK6 and DYRK2 inhibition in one compound to limit compensatory pathways, resistance, and toxicity.

A bladder hydrogel sustains local mitomycin C exposure while limiting systemic side effects.

This case uses pedaliin-containing Sesamum indicum leaf extract to reduce Aβ precursor expression and inhibit amyloid accumulation.

This case combines prebiotic fiber, a probiotic bacterium, and glutamine to accelerate brain maturation and learning in preterm infants.

A 35–67 m²/g surface-area range improves DKP microparticle respirability, adsorption, and uniform pulmonary dosing.

Amino acid changes redirect AAVrh74 tropism toward muscle, lowering liver loss and vector doses for gene delivery.

This case uses a piperidinedione E3 ligase binder in PROTACs to improve targeted protein degradation for therapeutic applications.

Engineered polynucleotides target conserved pathogen repeats to limit resistance.

This case uses an irreversible covalent BTK inhibitor to address incomplete B cell depletion and reduce Sjögren's syndrome activity.

Intravenous anti-CGRP antibodies target and neutralize CGRP, addressing delayed relief and supporting migraine prevention.

This case uses defined mirdametinib particle sizes in oral dosage forms to balance rapid release with pharmacokinetic control.

This case uses selective p300/CBP histone acetyltransferase inhibition to block CIC-DUX4 activation and reduce tumor growth.

The case uses validated snoRNA markers and expression feedback to identify and regulate cell de-servitization states.

A tumor-targeted cerium oxide nanoparticle blocks TGFβ-driven CAF activation, improving doxorubicin therapy and limiting metastasis.

Three-stage yeast fermentation reaches 5000 ppm NMN while avoiding chemical by-products.

Controlled crystallization produces Form HB, limiting polymorphic conversion and supporting consistent drug processing and storage.

Targeted TNFα inhibitors address limited treatment options for inflammatory disease.

Controlled-release implant coatings combine surface features and active agents to support osseointegration and reduce infection risk.

Formula I compounds selectively inhibit PARP1, trap it on DNA, and induce breaks to target HRD cancers with reduced toxicity.

This case combines perillyl alcohol with rolipram in a carbamate to target resistant glioma cells and tumor growth.

This case uses a heterocyclic HDAC6 inhibitor to increase acetylated tubulin, stabilize microtubules, and improve cognition in mice.

Inverse agonists and competitive antagonists target MRGPR X2 to reduce mast cell degranulation, itch, pain, and inflammation.

Emulsifiers limit phase coalescence and shear damage in biphasic transdermal matrices for consistent drug delivery.

Macrocyclic structures enable kinase inhibitors to cross the blood-brain barrier while maintaining potent activity against Met, Src, and CSF1R.

Phycocyanin composition suppresses joint pain and mobility decline, addressing locomotive syndrome prevention gaps in aging populations.

Triazolo(4,5-d)pyrimidine derivatives inhibit bacterial growth and penetrate membranes.

Combining Apremilast with Rifaximin creates a synergistic pharmaceutical composition targeting inflammatory pathways and gut microbiota simultaneously.

Dialysis adjusts chitosan pH to 6.2–7.2, preventing tissue necrosis while preserving injectability and long-term filling effects.

Nucleic acid barcodes track cell proliferation rates to identify candidate compounds that counteract toxic proteins in scalable screening assays.

Glycofurol-based paracetamol compositions enable high-concentration parenteral delivery with low viscosity.

A microcapsule hydrogel formulation controls drug release rates to maintain constant blood levels over time.

Replacing hazardous reagents with safer alternatives reduces environmental impact and by-product formation while maintaining high yield in the synthesis of this tetracyclic compound.

Formula I phthalazine compounds modulate p38 kinase activity, resolving specificity trade-offs in treating inflammatory diseases.

Heat-treated plasma proteins form a carrier that reduces toxicity while stimulating cell-mediated immunoreactions against tumors.

A liposome formulation encapsulates Wnt signal pathway inhibitors using a concentration gradient mechanism to achieve high loading efficiency.

Pyrimidinyl compounds inhibit ATR kinase to sensitize tumors, overcoming limited targeting in conventional chemotherapy.

Intermittent succinic anhydride addition during esterification controls hypromellose acetate succinate solution viscosity.

A butenafine hydrochloride aqueous patch dissolves the drug in a glycol salicylate and propylene glycol mixture within a hydrogel paste.

LNP compositions use a binding element to enhance mRNA stability and protein translation levels.

Selective muscarinic agonists inhibit cAMP synthesis via Gi/o coupling, reducing addiction risks associated with opioid treatments.

Deconstructed soil modulates gut microbiota by creating a chemical environment that favors beneficial species while reducing harmful pathogens.

An oral testosterone undecanoate formulation using a self-emulsifying surfactant system bypasses first-pass metabolism to maintain steady serum levels.

Fatty acid glycerol ester composition restores retina position via density gradient and surface tension, eliminating surgical removal needs.

Auto-modified PARP polymers conjugate antibodies and cytotoxic agents, resolving the trade-off between broad treatment coverage and targeted specificity.

Surface stabilizers suppress delamanid particle aggregation during aqueous milling, enhancing dissolution rates while eliminating organic solvent costs.

Dihydrooxadiazinone compounds modulate PDE3A-B-SLFN12 complexes, inhibiting tumor proliferation while sparing cardiac tissue.

Formula I and II compounds inhibit mTOR signaling to reduce cyst cell proliferation in polycystic kidney disease models.

Cationic steroidal antimicrobial compounds overcome antifungal resistance by disrupting fungal cell membranes while minimizing systemic side effects.

Electrospinning deposits everolimus onto a nitrogen-doped titanium oxide layer to form stable covalent bonds without polymer carriers.

Heterobifunctional small molecules recruit VHL or CRBN E3 ligases to degrade androgen receptor proteins.

Polysaccharide coating encapsulates free amino acids to enhance taste masking and stability in concentrated dietary supplements.

Replacing toxic tin reagents with boronic acids simplifies purification and yields a stable mesylate monohydrate salt for pharmaceutical use.

Modular oxysterol structures inhibit aberrant Hedgehog pathway activation to treat cancers like basal cell carcinoma.

Chimeric antigen receptor targets glypican-1 on squamous cell carcinoma cells, resolving weak cytotoxicity in solid tumors.

Specific antibodies neutralize dabigatran, resolving bleeding risks without removing the drug.

Modified flavone compounds inhibit hepatitis C virus entry while reducing side effects and overcoming drug resistance.

Amide compounds inhibit complement Factor D to reduce excessive activation and cellular damage in inflammatory disorders.

Novel fused heterocyclic compound with carbamoyl groups inhibits CDK8 and CDK19 enzymes.

Formula I compound crosses the blood-brain barrier to inhibit NLRP3 in microglia, overcoming poor brain penetration of existing treatments.

Electrostatic assembly of antibody-conjugated nanoparticles protects siRNA from nuclease degradation and extends circulation time.

pH-sensitive peptide conjugates selectively release topoisomerase I inhibitors in acidic tumor microenvironments, reducing systemic toxicity.

A one-step process couples cell-binding agents to cytotoxic agents using a bifunctional crosslinking reagent in a controlled pH solution.

Topical C2-C5 polycarboxylic acids enhance blue light penetration into the stratum corneum, achieving a log reduction of at least 2 in P. acnes counts.

Combining naporafenib with trametinib, rineterkib, or ribociclib improves progression-free survival while reducing QTc prolongation and skin toxicity.

Controlled surface roughness and hydroxyapatite coatings on biomedical implants mitigate chronic inflammation and fibrosis while maintaining structural support.

Pyrimidine-based Btk inhibitors mobilize hematopoietic stem cells to peripheral blood, addressing chemotherapy-induced leukopenia and neutropenia.

Bio-based pharmaceutical compounds utilize 14C isotopic signatures to signal renewable origin and enhance patient adherence.

Liposomal curcumin sensitizes glioblastoma cells via ceramide elevation, restoring responsiveness in patients unresponsive to standard chemotherapy.

Small molecule isoquionline derivatives block inhibitory immune pathways to resolve T cell exhaustion in cancer treatment.